Investor & Media Relations

We discover and develop medicines to defeat neurodegeneration.

The science is breaking open and the time is right for an ambitious and rigorous effort to address Alzheimer’s disease, Parkinson’s disease, ALS and other neurodegenerative diseases. We are applying deep scientific and drug development expertise to discover effective molecular therapeutics and have engineered a proprietary technology to deliver biologic therapeutics to the brain.

With a team of experienced and passionately dedicated scientists and drug developers, we believe we can succeed in meaningfully improving the lives of patients and their families.

Denali Nasdaq

Press Releases

Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 11, 2025

Read More
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)

Jul 07, 2025

Read More
Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

May 06, 2025

Read More


VIEW ALL


Events

Jun 10, 2025 from 1:20 PM to 1:55 PM EDT

Goldman Sachs Webcast

Listen to webcast

VIEW ALL

Corporate Presentation


  • Change

  • Volume

  • Market Cap

  • Today's Open

  • Previous Close

  • Exchange

    NASDAQ

  • Today's High

  • Today's Low

  • 52 Week High

  • 52 Week Low

Minimum 15 minutes delayed. Source: LSEG

Analyst Coverage

View detailed list of firms and analysts.

View Coverage

SEC Filing

View, download, and share all SEC Filing documents.

View Documents

Corporate Governance

View, download, and share Corporate Governance documents.

View Documents

FAQs

Sign up for email alerts

Stay in the loop with updates on the latest Denali news delivered right to your inbox